CD8A and neoplasm: Also in 2017, another preclinical study by Freedman et al. reported that an adenovirus expressing EpCAM/CD3–specific BiTEs could improve the penetration and activation of both CD4+ and CD8+ T cells, thus enhancing T cell-mediated tumor killing in clinical tissue biopsy samples containing EpCAM-positive tumor cells (105).